Filtered By:
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 1360 results found since Jan 2013.

Role of Preexisting Disability in Patients Treated With Intravenous Thrombolysis for Ischemic Stroke Clinical Sciences
Conclusions— Prestroke disability does not seem to independently increase the risk of symptomatic intracranial hemorrhage after thrombolysis. Despite higher mortality, 1 in 3 previously disabled patients may return to his/her prestroke mRS. Therefore, they should not be routinely excluded from thrombolytic therapy.
Source: Stroke - February 24, 2014 Category: Neurology Authors: Karlinski, M., Kobayashi, A., Czlonkowska, A., Mikulik, R., Vaclavik, D., Brozman, M., Svigelj, V., Csiba, L., Fekete, K., Korv, J., Demarin, V., Vilionskis, A., Jatuzis, D., Krespi, Y., Ahmed, N., Wahlgren, N., for the Safe Implementation of Treatments i Tags: Thrombolysis Clinical Sciences Source Type: research

Stroke and Cardiac Papillary Fibroelastoma: Mechanical Thrombectomy after Thrombolytic Therapy
We describe a case of a 34-year-old man with a sudden development of right hemiparesis and aphasia because of infarction of the left middle cerebral artery that was submitted to intravenous (IV) recombinant tissue plasminogen activator and mechanical thrombectomy. Transesophageal echocardiogram showed a small mass on the anterior leaflet of the mitral valve. Cardiac surgery was performed, and histological examination of the removed material was consistent with cardiac papillary fibroelastoma (CPF). Experience in using IV thrombolysis for the treatment of embolic stroke because of CPF is limited. To the best of our knowledg...
Source: Journal of Stroke and Cerebrovascular Diseases - October 21, 2013 Category: Neurology Authors: Ana F. Santos, João Pinho, Vítor Ramos, Joana Pardal, Jaime Rocha, Carla Ferreira Tags: Case Reports Source Type: research

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban
As limited amounts of data are available regarding thrombolytic therapy for patients taking novel oral anticoagulants, thrombolytic therapy is not recommended in such cases. Here, we report an acute stroke patient taking rivaroxaban who received intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA). An 80-year-old man with a history of nonvalvular atrial fibrillation, who had been receiving 10 mg of rivaroxaban showed abrupt onset of aphasia and right hemiparesis. National Institutes of Health Stroke Scale score was 10.
Source: Journal of Stroke and Cerebrovascular Diseases - September 30, 2014 Category: Neurology Authors: Hideyuki Ishihara, Hiroaki Torii, Hirochika Imoto, Fumiaki Oka, Hirokazu Sadahiro, Michiyasu Suzuki Tags: Case Report Source Type: research

Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Original Articles
Conclusions— Presence of CKD among patients with IS treated with intravenous tissue-type plasminogen activator is associated with higher unadjusted odds of symptomatic intracranial hemorrhage or serious systemic hemorrhage, but this is explained by non-CKD related factors.
Source: Circulation: Cardiovascular Quality and Outcomes - November 18, 2014 Category: Cardiology Authors: Ovbiagele, B., Smith, E. E., Schwamm, L. H., Grau-Sepulveda, M. V., Saver, J. L., Bhatt, D. L., Hernandez, A. F., Peterson, E. D., Fonarow, G. C. Tags: Cerebrovascular disease/stroke, Risk Factors, Acute Cerebral Infarction, Thrombolysis Original Articles Source Type: research

Response to Letter Regarding Article, "Defining Clinically Relevant Cerebral Hemorrhage After Thrombolytic Therapy for Stroke: Analysis of the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator Trials" Letters to the Editor
Source: Stroke - January 26, 2015 Category: Neurology Authors: Rao, N. M., Levine, S. R., Saver, J. L. Tags: Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Emergency treatment of Stroke, Intracerebral Hemorrhage, Thrombolysis Letters to the Editor Source Type: research

Cerebral hemorrhage following thrombolytic therapy for stroke: Are neutrophils really neutral?
An ideal biomarker can accurately predict disease risk stratification. The longstanding link between inflammatory responses and atherosclerotic disease and vascular events suggests great promise for inflammatory measures as biomarkers in stroke and other vascular disease. Recent studies across multiple areas and disciplines have suggested that leukocytes, as an inflammatory marker, and specifically neutrophils, may hold promise in predicting poor outcomes in various cardiovascular diseases (e.g., heart failure, acute coronary syndromes, stable coronary artery disease), including stroke, as well as in neoplasms, infections,...
Source: Neurology - October 19, 2015 Category: Neurology Authors: Roever, L., Levine, S. R. Tags: All Cerebrovascular disease/Stroke, All epidemiology, Prevalence studies, Risk factors in epidemiology, Intracerebral hemorrhage EDITORIALS Source Type: research

Cognitive Outcomes following Thrombolysis in Acute Ischemic Stroke: A Systematic Review
Patients treated with thrombolytic therapy within 4.5 hours after stroke onset appear to have improved survival and functional outcomes. Poststroke cognitive impairment is associated with reduced quality of life and survival and needs to be reviewed in consideration of the administration of thrombolysis. This review aims to systematically evaluate literature exploring the effect of thrombolysis for ischemic stroke on cognition.
Source: Journal of Stroke and Cerebrovascular Diseases - August 25, 2016 Category: Neurology Authors: Laura Jayne Broome, Ceri Elisabeth Battle, Matthew Lawrence, Phillip Adrian Evans, Michael Stuart Dennis Source Type: research

The effect of statin use in acute ischemic stroke patients treated with thrombolytic therapy
This study investigated the effects of statins for the acute ischemic stroke patients after thrombolysis on the stroke outcome considering statin intensity and time window.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Jong-Moo Park, Tae Kyoung Kim, Eui Sung Jung, Kyusik Kang, Woung-Woo Lee, Jungju Lee, Ohyun Kwon, Byung-Kun Kim Source Type: research

Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)
Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Barazangi, N., Sorensen, S., Chen, C., Wong, C., Yee, A., Ke, M., Rose, J., Grosvenor, D., Bedenk, A., Fernandes, J., Tong, D. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research

Talk About Thrombolysis. Regular Case-Based Discussions of Stroke Thrombolysis Improve Door-to-Needle Time by 20%.
Background: The outcome of stroke patients can be improved by a rapid initiation of thrombolytic therapy. Here, we sought to determine whether an additional simple but thorough case-based discussion of recent thrombolysed cases with the entire neurologic staff can improve the door-to-needle time without changes to the implemented stroke protocol. Methods: For every performed thrombolysis, a route card, consisting of a timeline with 3 time points and target times, had to be completed by the attending neurologist.
Source: Journal of Stroke and Cerebrovascular Diseases - December 28, 2018 Category: Neurology Authors: Caroline Klingner, Albrecht G ünther, Stefan Brodoehl, Otto W. Witte, Carsten M. Klingner Source Type: research

The First 10 Thrombolysis for Acute Ischemic Stroke in Lao People's Democratic Republic under Teleconsultation from Thailand
This study aimed to evaluate the feasibility and safety of thrombolytic therapy administration at Mittaphab Hospital, Lao PDR under the international telestroke consultation system from King Chulalongkorn Memorial Hospital, Thailand. Methods: Acute ischemic stroke patients who presented at Mittaphab Hospital within 4.5 hours after the onset and received thrombolytic therapy between December 2016 and June 2017 were studied.
Source: Journal of Stroke and Cerebrovascular Diseases - September 13, 2019 Category: Neurology Authors: Aurauma Chutinet, Saysavath Keosodsay, Pongpat Vorasayan, Jitlada Samajarn, Wasan Akarathanawat, Naruchorn Kijpaisalratana, Naly Norsakpeseuth, Ketmany Phetsiriseng, Snong Thongsna, Pakkawan Vongvasinkul, Nijasri C. Suwanwela Source Type: research

Is Door-to-Needle Time Reduced for Emergency Medical Services Transported Stroke Patients Routed Directly to the Computed Tomography Scanner on Emergency Department Arrival?
A nationally recommended practice to accelerate thrombolytic therapy for acute ischemic stroke is to route emergency medical services (EMS)-transported stroke patients directly to the computed tomography (CT) scanner on arrival. We evaluated door-to-needle time with direct-to-CT routing versus emergency department (ED)-bed first routing.
Source: Journal of Stroke and Cerebrovascular Diseases - November 3, 2019 Category: Neurology Authors: Bryan Sloane, Nichole Bosson, Nerses Sanossian, Jeffrey L. Saver, Lorrie Perez, Marianne Gausche-Hill Source Type: research

Efficacy and Safety of Thrombolytic Therapy for Stroke with Unknown Time of Onset: A Meta-Analysis of Observational Studies
Recombinant tissue plasminogen activator (rt-PA) is one of the most effective therapies available for patients with known-onset stroke (KOS). Whether rt-PA treatment would improve functional outcomes in patients with stroke with unknown time of onset (UTOS) is undetermined, we aimed to systematically assess the efficacy and safety of thrombolysis for UTOS patients in this meta-analysis.
Source: Journal of Stroke and Cerebrovascular Diseases - February 28, 2020 Category: Neurology Authors: Ruo-lin Zhu, Jing Xu, Cheng-juan Xie, Ying Hu, Kai Wang Source Type: research

Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy
The ability to remain in employment addresses an important consequence of stroke beyond the usual clinical parameters. However, data on the association between time to intravenous thrombolysis and workforce attachment in patients with acute ischemic stroke are sparse.
Source: Journal of Stroke and Cerebrovascular Diseases - August 24, 2021 Category: Neurology Authors: Jawad H. Butt, Kristian Kragholm, Christina Kruuse, Hanne Christensen, Helle K. Iversen, S øren Paaske Johnsen, Rasmus Rørth, Naja Emborg Vinding, Adelina Yafasova, Christine Benn Christiansen, Gunnar H. Gislason, Christian Torp-Pedersen, Lars Køber, E Source Type: research

Recombinant tissue plasminogen activator (rTPA) management for first onset acute Ischemic Stroke with covid -19 and non-covid -19 patients
In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute ischemic stroke (AIS) patients with or without Covid-19 infection.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2023 Category: Neurology Authors: Eman M Khedr, Ahmed Abdelwarith, Gehad M Moussa, Mostafa Saber Source Type: research